Overview of the LUX-Lung Clinical Trial Program of Afatinib for Non –Small Cell Lung Cancer

Lung cancer is one of the most common cancers and accounts for 26% of all cancer deaths [1]. There will be an estimated 222,500 new cases of lung cancer and approximately 155,870 associated deaths in the United States in 2017 [1]. Lung cancers are divided into non –small cell lung cancer (NSCLC; ∼80%-85%) and small cell lung cancer (SCLC; ∼10%-15%) [2]. Pathologically, NSCLC is further divided into adenocarcinoma (∼40%), squamous cell carcinoma (SCC; ∼25%-30%), and large cell carcinoma (∼10%-15%) [2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research